Article

Study: 123 million+ lost workdays per year caused by blindness or eye diseases

The European Forum Against Blindness (EFAB) has revealed the results of an 11-country study-an extension to the data reported last year covering six countries-which reports on the economic impact of blindness and four leading eyesight conditions, and concluded that blindness and vision loss lead to a reduced quality of life and increased economic burden to society.

Brussels, Belgium-The European Forum Against Blindness (EFAB) has revealed the results of an 11-country study-an extension to the data reported last year covering six countries-which reports on the economic impact of blindness and four leading eyesight conditions, and concluded that blindness and vision loss lead to a reduced quality of life and increased economic burden to society.

In case you missed it: FDA clears Rayner mini-incision injector

"The key consideration and the direct call to action from this report is that investing in earlier and more targeted interventions-for example, screening for diabetic retinopathy and glaucoma followed by treatment, anti-VEGF treatment as standard of care for wet AMD-would lead to a healthier population and help alleviate the cost of blindness," said professor Ian Banks, chairman of European Men's Health Forum (EMHF) and EFAB.

The topline results from the study, conducted by the independent health economics group, Deloitte Access Economics, can be accessed via the interactive analytical tool for blindness and vision impairment, which is available on http://www.efabeu.org/analytics.

The study-covering Denmark, France, Germany, Ireland, Italy, Poland, Slovakia, Spain, Sweden, Switzerland, and the United Kingdom, reported that in these 11 countries:

·      862,067 people are blind

·      Many people suffer from debilitating sight loss resulting from

o   Cataracts: 29,184,875

o   Diabetic retinopathy: 3,637,458

o   Glaucoma: 4,466,224

o   Wet age-related macular degeneration (wet AMD): 2,013,228

Blindness and the four eye diseases lead to a significant reduction in well being, equivalent to 123 million workdays lost per year.

 

Blindness and the eye diseases are estimated to result in annual economic costs of approximately 8 and 24 billion Euro respectively, across the countries studied.

The study concluded that each cost-effective intervention can off set economic costs in the range of 2 to 3 billion Euros. These interventions included anti-VEGF treatment as standard of care for wet AMD, appropriate early detection, prevention and treatment options, such as screening for cataracts, diabetic retinopathy, and glaucoma followed by treatment.

"In the EU-11, the four eye diseases affect approximately 1 in 10 people, and these conditions don't only impact those directly affected, but their carers, family members, and friends," Banks said. "Then, there is the considerable economic burden of blindness and vision loss to society to consider. For blindness, over 50% of this cost is from informal care."

 

For more articles in this issue of Ophthalmology Times eReport, click here.

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.